跳转至内容
Merck
CN

Pharmacogenetics in schizophrenia: a review of clozapine studies.

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) (2013-10-22)
Fabiana Barzotti Kohlrausch
摘要

Clozapine is quite effective to treat schizophrenia, but its use is complicated by several factors. Although many patients respond to antipsychotic therapy, about 50% of them exhibit inadequate response, and ineffective medication trials may entail weeks of unremitted illness, potential adverse drug reactions, and treatment nonadherence. This review of the literature sought to describe the main pharmacogenetic studies of clozapine and the genes that potentially influence response to treatment with this medication in schizophrenics. We searched the PubMed database for studies published in English in the last 20 years using keywords related to the topic. Our search yielded 145 studies that met the search and selection criteria. Of these, 21 review articles were excluded. The 124 studies included for analysis showed controversial results. Therefore, efforts to identify key gene mechanisms that will be useful in predicting clozapine response and side effects have not been fully successful. Further studies with new analysis approaches and larger sample sizes are still required.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
氯氮平标准液
Supelco
氯氮平标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
氯氮平标准液, United States Pharmacopeia (USP) Reference Standard
氯氮平标准液, European Pharmacopoeia (EP) Reference Standard
USP
氯氮平标准液, United States Pharmacopeia (USP) Reference Standard
氯氮平,用于谱峰鉴别, European Pharmacopoeia (EP) Reference Standard